Modified nucleic acids: replication, evolution, and next-generation therapeutics

Modified nucleic acids, also called xeno nucleic acids (XNAs), offer a variety of advantages for biotechnological applications and address some of the limitations of first-generation nucleic acid therapeutics. Indeed, several therapeutics based on modified nucleic acids have recently been approved and many more are under clinical evaluation. XNAs can provide increased biostability and furthermore are now increasingly amenable to in vitro evolution, accelerating lead discovery. Here, we review the most recent discoveries in this dynamic field with a focus on progress in the enzymatic replication and functional exploration of XNAs.

Abstract licence: CC BY-NC-ND

1. 76.

   A general strategy for expanding polymerase function by droplet microfluidics · 2016

2. 158.

   Cell-Penetrating Peptides to Enhance Delivery of Oligonucleotide-Based Therapeutics · 2018

3. 207.

   RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs · 2020

210 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.